RNAC Cartesian Therapeutics Inc

Price (delayed)

$6.58

Market cap

$193.33M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.9

Enterprise value

$86.54M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 16
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 18

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic ...

Highlights
The company's debt fell by 16% YoY and by 6% QoQ
RNAC's gross profit has shrunk by 95% YoY and by 37% QoQ
RNAC's revenue has dropped by 95% year-on-year and by 37% since the previous quarter

Key stats

What are the main financial stats of RNAC

RNAC stock price

How has the Cartesian Therapeutics stock price performed over time
Intraday
5.03%
1 week
-8.74%
1 month
-5.05%
1 year
-31.03%
YTD
-8.74%
QTD
6.99%

Financial performance

How have Cartesian Therapeutics's revenue and profit performed over time
Revenue
$1.78M
Gross profit
$1.78M
Operating income
-$148.02M
Net income
-$151.77M
Gross margin
100%
Net margin
-8,550.6%
The operating income has shrunk by 182% YoY and by 3.2% QoQ
RNAC's gross profit has shrunk by 95% YoY and by 37% QoQ
RNAC's revenue has dropped by 95% year-on-year and by 37% since the previous quarter
The company's net margin has shrunk by 84% QoQ

Price vs fundamentals

How does RNAC's price correlate with its fundamentals

Growth

What is Cartesian Therapeutics's growth rate over time

Valuation

What is Cartesian Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
99.55
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
48.76
The company's EPS fell by 18% QoQ
The company's equity fell by 17% QoQ
RNAC's P/S is 153% higher than its 5-year quarterly average of 37.4 but 43% lower than its last 4 quarters average of 166.7
RNAC's revenue has dropped by 95% year-on-year and by 37% since the previous quarter

Efficiency

How efficient is Cartesian Therapeutics business performance
The company's return on sales has shrunk by 82% QoQ
The return on assets has declined by 29% since the previous quarter
Cartesian Therapeutics's ROIC has decreased by 27% from the previous quarter

Dividends

What is RNAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RNAC.

Financial health

How did Cartesian Therapeutics financials performed over time
Cartesian Therapeutics's total assets is 34% less than its total liabilities
The quick ratio is down by 39% YoY and by 12% QoQ
RNAC's current ratio is down by 38% YoY and by 12% QoQ
The company's debt is 108% higher than its equity
Cartesian Therapeutics's debt to equity has soared by 88% YoY and by 20% from the previous quarter
The company's equity fell by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.